Ampac's fine chemical segment reported FY12 revenues of $111.5m up 25% on 2011. The company attributed this improvement to a recovery from a lag in antiviral product sales in 2011 and to growth from existing or new products.
Seeking Alpha
Thursday 20 December 2012
Ampac revenues rise
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment